BillionToOne Expands Its Leadership in Hemolytic Disease of the Fetus and Newborn (HDFN) and Extends Fetal Antigen Testing to Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) MENLO PARK, Calif., ...
PlateletBio, a company developing a new class of cell therapies based on the biology of platelets, has raised $75.5 million to advance its drug pipeline, including a lead candidate for a rare bleeding ...
SAN DIEGO (Reuters) - Scientists have for the first time created blood platelet cells by reprogramming stem cells derived from adult cells, offering the potential for a renewable supply of the fragile ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results